{"task_id": "2de00320caa1022e", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 870/905)", "text": "ttp://www.\nclinexprheumatol.org/article.asp?a=2873\n\n--- Page 876 ---\n862\nReferences\n18 Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best \nPract Res Clin Rheumatol 2007; 21(5):907\u201327. http://www.bprclinrheum.com/article/S1521-6942(07)00063-\n0/abstract\n19 Farid SS, Azizi G, Mirsha\ufb01 ey A. Anti-citrullinated protein antibodies and their clinical utility in rheuma-\ntoid arthritis. Int J Rheum Dis 2013; 16(4):379\u201386. http://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12129/\nabstract\n20 Brown AK, Wake\ufb01 eld RJ, Conaghan PG, et al. New approaches to imaging early in\ufb02 ammatory arthri-\ntis. Clin Exp Rheumatol 2004; 22(5 Suppl 35): S18\u201325. http://www.clinexprheumatol.org/article.asp?a=2432\n21 Szekanecz Z, Kerekes G, D\u00e9r H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad \nSci 2007; 1108:349\u201358. http://onlinelibrary.wiley.com/doi/10.1196/annals.1422.036/abstract\n22 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classi\ufb01 cation criteria: an American \nCollege of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum \n2010; 62(9):2569\u201381. http://onlinelibrary.wiley.com/doi/10.1002/art.27584/abstract\n23 O\u2019Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350:2591\u2013602. http://\nwww.nejm.org/doi/full/10.1056/NEJMra040226 \n24 British Society for Rheumatology. National guidelines for the monitoring of second line drugs. 2000. http://\nwww.rheumatology.org.uk/includes/documents/cm_docs/2009/m/monitoring_second_line_drugs.pdf \n25 NICE. Adalimumab, etanercept and in\ufb02 iximab for the treatment of rheumatoid arthritis [TA130]. \n2007. https://www.nice.org.uk/guidance/ta130\n26 NICE. Adalimumab, etanercept, in\ufb02 iximab, rituximab and abatacept for the treatment of rheuma-\ntoid arthritis after the failure of a TNF inhibitor [TA195]. 2010. https://www.nice.org.uk/guidance/ta195\n27 NICE. Tocilizumab for the treatment of rheumatoid arthritis [TA247]. 2012. https://www.nice.org.uk/\nguidance/ta247\n28 NICE. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-\nmodifying anti-rheumatic drugs [TA234]. 2011. https://www.nice.org.uk/guidance/ta234\n29 Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic lit-\nerature review informing the 2013 update of the EULAR recommendations for management of rheumatoid \narthritis. Ann Rheum Dis 2014; 73(3):529\u201335\n30 Thompson A, Gandhi KK, Hochberg MC, et al. Incidence of malignancy in adult patients with rheu-\nmatoid arthritis: a meta-analysis. Arthritis Res Ther 2015; 17(1):212. https://www.ncbi.nlm.nih.gov/pmc/\narticles/PMC4536786/\n31 Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Di-\nagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including \nTherapeutics (ESCISIT). Ann Rheum Dis 2006; 65(10):1301\u201311. https://www.ncbi.nlm.nih.gov/pmc/articles/\nPMC1798330/\n32 Sturrock R. Gout. Easy to misdiagnose. BMJ 2000; 320:132\u20133. https://www.ncbi.nlm.nih.gov/pmc/arti-\ncles/PMC1128728/\n33 Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Profes-\nsionals in Rheumatology guideline for the management of gout. Rheumatology 2007; 46(8):1372\u20134. http://\nrheumatology.oxfordjournals.org/content/46/8/1372.full\n34 Cronstein BN, Terkeltaub R. The in\ufb02 ammatory process of gout and its treatment. Arthritis Res Ther \n2006; 8 Suppl 1:S3. https://arthritis-research.biomedcentral.com/articles/10.1186/ar1908\n35 Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients \nwith hyperuricemia and gout. N Engl J Med 2005; 353(23):2450\u201361. http://www.nejm.org/doi/full/10.1056/\nNEJMoa050373\n36 Zhang W, Doherty M, Bardin T, et al. EULAR recommendations for calcium pyrophosphate deposition. \nPart II: Management. Ann Rheum Dis 2011; 70:571\u20135. http://ard.bmj.com/content/70/4/571.full\n37 Wanders A, Heijde DV, Landewe R, et al. Nonsteroidal antiin\ufb02 ammatory drugs reduce radiographic \nprogression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; \n52(6):1756\u201365. https://www.ncbi.nlm.nih.gov/pubmed/15934081\n38 NICE. Adalimumab, etanercept and in\ufb02 iximab for ankylosing spondylitis [TA143]. 2008. https://www.\nnice.org.uk/guidance/ta143\n39 Hakim A, Clunie G, Haq I (eds). Oxford handbook of rheumatology (3rd edn). Oxford: Oxford University \nPress, 2011\n40 Di Lorenzo AL. HLA-B27 syndromes. Medscape. 2015. http://emedicine.medscape.com/article/1201027-\noverview\n41 Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of \ufb01 brotic diseases such as systemic \nsclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010; 69 Suppl 1:i48\u201351. http://ard.bmj.\ncom/content/69/Suppl_1/i48.long\n42 Gross WL, Reinhold-Keller E. [ANCA-associated vasculitis (Wegener\u2019s granulomatosis, Churg-Strauss \nsyndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects.] Z Rheumatol \n1995; 54(5):279\u201390. https://www.ncbi.nlm.nih.gov/pubmed/8578884\n43 Rahman A. Systemic lupus erythematosus. N Engl J Med 2008; 358:929\u201339. http://www.nejm.org/doi/\nfull/10.1056/NEJMra071297\n44 NICE. Final appraisal determination. Belimumab for treating active autoantibody-positive systemic \nlupus erythematosus. 2016. https://www.nice.org.uk/guidance/GID-TAG273/documents/\ufb01 nal-appraisal-\ndetermination-document\n45 Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it \nis not rare. Transplantation 2003; 75(5):651\u20136. https://www.ncbi.nlm.nih.gov/pubmed/12640304 \n46 Baglin TP, Keeling DM, Watson HG. British Committee for Standards in Haematology. Guidelines on oral \nanticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006; 132(3):277\u201385. https://www.\nncbi.nlm.nih.gov/pubmed/16409292\n47 Petri M, Orbai AM, Alarc\u00f3n GS, et al. Derivation and validation of the Systemic Lupus International \nCollaborating Clinics classi\ufb01 cation criteria for systemic lupus erythematosus. Arthritis Rheum 2012; \n64(8):2677\u201386. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409311/\n48 Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference \nNomenclature of Vasculitides. Arthritis Rheum 2012; 65(1):1\u201311\n49 Trejo-Gutierrez JF, Larson JM, Abril A. Shortness of breath, weak pulses, and a high ESR. Lancet 2008; \n371:176. http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(08)60109-9.pdf", "text_length": 6580, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 870/905)", "type": "chunk", "chunk_index": 869, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:53.684932", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:53.687045", "status": "complete", "chunks_added": 4}